A sample report on
Norway Medical and
Diagnostic
Laboratory Service
Market Analysis
Includes Market Size, Market Segmented by Types
and Key Competitors (Data forecasts from 2022 – 2030F)
www.insights10.com
This report presents a strategic analysis of the Norway Medical and Diagnostic Laboratory Service Market Analysis and a forecast for its development in the medium and long term. It provides a comprehensive overview of the market value, dynamics, segmentation, types of clinical diagnostics, point-of-care testing, main players, growth and demand drivers, challenges & future outlook, etc. This is one of the most comprehensive reports about the Norway Medical and Diagnostic Laboratory Service Market Analysis, and offers unmatched value, accuracy, and expert insights
Report Scope
Report Attribute
Details
Number of Pages
70-80
Base Year for Estimation
2022
Forecast Period
2023-2030
Market Overview, Revenue Forecast, Market Segmentation, Growth Factors and Trends, Report Coverage
Competitive Landscape, Key Company Profiles, Government Policies, Regulatory Landscape, Reimbursement Scenario
Quantitative Units
Revenue in USD Million/Billion (Mn/Bn)
Research Approach
Secondary Research (60%), Primary Research (40%)
Click on the icon to know the detailed methodology
A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential 3
Table of Content
CONTENT
PG. NO.
1. Healthcare Diagnostics Overview
12-25
1.1. Overview
1.2. Norway Overview
1.3. Economic Overview: Norway
1.4. Healthcare Diagnostics Market in Norway
1.5. Healthcare Services Market in Norway
1.6. Healthcare Scenario in Norway
1.7. Health Insurance Coverage: Norway
1.8. Budget of the Government for Public Insurance
1.9. Mergers and Acquisitions
2. Market Size and Forecasting
2.1 Market size and forecasts (Excel and Methodology)
26-33
A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential 4
Table of Content
CONTENT
PG. NO.
2.2. Market Segmentation
2.2.1. By Test
2.2.2. By Product
2.2.3. By End User
3. Market Dynamics
34-38
3.1. Market Growth Drivers
3.1.1. Norway Medical and Diagnostic Laboratory Service Market Analysis Driver 1
3.1.2. Norway Medical and Diagnostic Laboratory Service Market Analysis Driver 2
3.1.3. Norway Medical and Diagnostic Laboratory Service Market Analysis Driver 3
3.2. Market Restraints
3.2.1. Norway Medical and Diagnostic Laboratory Service Market Analysis Restraint 1
3.2.2. Norway Medical and Diagnostic Laboratory Service Market Analysis Restraint 2
A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential 5
Table of Content
CONTENT
PG. NO.
3.2.3. Norway Medical and Diagnostic Laboratory Service Market Analysis Restraint 3
4. Competitive Landscape
39-49
4.1. Major Market Share
4.2. Key Company Profile
4.2.1. Vestre Viken HF
4.2.1.1. Overview
4.2.1.2. Product Applications & Services
4.2.1.3. Recent Developments
4.2.1.4. Partnerships Ecosystem
4.2.1.5. Financials (Based on Availability)
4.2.2. Fürst Medical Laboratory
4.2.2.1. Overview
A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential 6
Table of Content
CONTENT
PG. NO.
4.2.2.2. Product Applications & Services
4.2.2.3. Recent Developments
4.2.2.4. Partnerships Ecosystem
4.2.2.5. Financials (Based on Availability)
4.2.3. Sykehusapotekene
4.2.3.1. Overview
4.2.3.2. Product Applications & Services
4.2.3.3. Recent Developments
4.2.3.4. Partnerships Ecosystem
4.2.3.5. Financials (Based on Availability)
4.2.4. Norgesplaster
4.2.4.1. Overview
A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential 7
Table of Content
CONTENT
PG. NO.
4.2.4.2. Product Applications & Services
4.2.4.3. Recent Developments
4.2.4.4. Partnerships Ecosystem
4.2.4.5. Financials (Based on Availability)
4.2.5. Unilabs
4.2.5.1. Overview
4.2.5.2. Product Applications & Services
4.2.5.3. Recent Developments
4.2.5.4. Partnerships Ecosystem
4.2.5.5. Financials (Based on Availability)
4.2.6. SYNLAB Norge
4.2.6.1. Overview
A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential 8
Table of Content
CONTENT
PG. NO.
4.2.6.2. Product Applications & Services
4.2.6.3. Recent Developments
4.2.6.4. Partnerships Ecosystem
4.2.6.5. Financials (Based on Availability)
4.2.7. Aleris
4.2.7.1. Overview
4.2.7.2. Product Applications & Services
4.2.7.3. Recent Developments
4.2.7.4. Partnerships Ecosystem
4.2.7.5. Financials (Based on Availability)
4.2.8. Quantum Diagnostics Sdn Bhd
4.2.8.1. Overview
A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential 9
Table of Content
CONTENT
PG. NO.
4.2.8.2. Product Applications & Services
4.2.8.3. Recent Developments
4.2.8.4. Partnerships Ecosystem
4.2.8.5. Financials (Based on Availability)
4.2.9. Oslo University Hospital
4.2.9.1. Overview
4.2.9.2. Product Applications & Services
4.2.9.3. Recent Developments
4.2.9.4. Partnerships Ecosystem
4.2.9.5. Financials (Based on Availability)
4.2.10. Helse Bergen
4.2.10.1. Overview
A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential 10
Table of Content
CONTENT
PG. NO.
4.2.10.2. Product Applications & Services
4.2.10.3. Recent Developments
4.2.10.4. Partnerships Ecosystem
4.2.10.5. Financials (Based on Availability)
5. Reimbursement Scenario
50-57
5.1. Reimbursement Regulation
5.2. Reimbursement Process for Diagnosis of Diseases
5.3. Reimbursement Process for Treatment of Diseases
5.4. Reimbursement Process – Medicare
5.5. Reimbursement Process - Medicaid
6. Methodology & Scope
58-63
A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential 11
Norway Medical and Diagnostic Laboratory Service Market Analysis 1. Healthcare Diagnostics Overview
1.1 Statistics at a Glance: The Scenario of Healthcare Diagnostics in the World Scope of Healthcare Diagnostics
▪
Please be aware that this sample report is
intended to provide you with a brief
overview of the kind of information and
165.58 Bn
analysis that will be presented in the final
Global diagnostic market
report
stood at USD 165.58 Bn in
2021
68.96%
▪
In this section you will get an
non-communicable
understanding of the topic, which includes
diseases are responsible
the prevalence of the disease, the
for 74% of all fatalities in
application of medical devices, new
World
technology, and other details related to the
3.24%
topic
Diagnostics segment in
globe is projected to grow
▪
In order to obtain access to all of the
by 3.24% (2023-2027)
information that you are seeking, you will
resulting in a market
need to purchase the final report
volume of $348.75 Bn in
▪
Final report will be comprehensive and
2030
detailed, and it will include data, analysis,
trends, and other relevant information
related to the topic or subject matter of
interest
A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential 13
1.1 Statistics at a Glance: The Scenario of Healthcare Diagnostics in the World (continued)
Europe
~Revenue to reach
$xx Bn by 2027
North America
~ Market Size of
Asia
$xx Bn
-Fastest CAGR
Africa
Egypt Market
~Market Size of $xx
~$xx Market
Illustrative
A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential 14
1.2 Norway Overview
▪
Please be aware that this sample report is
intended to provide you with a brief
overview of the kind of information and
analysis that will be presented in the final
report
▪
In this section you will get an
understanding of the demographics of the
country/region, which includes the
5.54 Mn
489.68 Bn
population, GDP, healthcare expenditure
and other details related to the topic
Is the population of
Is the Gross
Norway, in 2023
Domestic Product
▪
In order to obtain access to all of the
(GDP) in Norway in
information that you are seeking, you will
2023
need to purchase the final report
▪
Final report will be comprehensive and
34.68
$89,154.28
detailed, and it will include data, analysis,
Is the median age
per capita was the
trends, and other relevant information
in Norway, in 2022
amount of national
related to the topic or subject matter of
health expenditures in
interest
2022
A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential 15
1.3 Economic Overview: Norway
Population of Norway, (2020-2030)
GDP of Norway, (2020-2030)
XX
XX
XX
XX
2020
2021
2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F
2020
2021
2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F
Population Split (2023)
▪
In this section you will get an understanding of the demographics of the country/region, which includes the population, GDP, By Gender
By Age Group
healthcare expenditure and other details related to the topic
▪
In order to obtain access to all of the information that you are 0-14
seeking, you will need to purchase the final report
15-24
Female
Male
▪
Final report will be comprehensive and detailed, and it will 51%
49%
25-54
include data, analysis, trends, and other relevant information 55-64
related to the topic or subject matter of interest
65+
Illustrative
A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential 16
1.4 Statistics at a Glance: The Scenario of Healthcare Diagnostics in the Norway
Scope of Healthcare Diagnostics
▪
Please be aware that this sample report is
intended to provide you with a brief
overview of the kind of information and
$3.2 billion
1258.65 Mn
analysis that will be presented in the final
Norway’s healthcare
Norway Medical and
report
expenditures are expected to
diagnostic market stood at
double to $3.2 billion by
USD 1011.24 Million in 2021
▪
In this section you will get an
2028
understanding of the topic, which includes
the prevalence of the disease, the
application of medical devices, new
technology, and other details related to the
4.58%
68.59%
topic
Diagnostics segment in
non-communicable
Norway is projected
▪
In order to obtain access to all of the
diseases are responsible
to grow by 4.58% (2023-
information that you are seeking, you will
for 68.59% of all fatalities
2027) resulting in a market
need to purchase the final report
in Norway
volume of US$1235.58 Mn
▪
Final report will be comprehensive and
in 2027
detailed, and it will include data, analysis,
trends, and other relevant information
related to the topic or subject matter of
interest
A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential 17
1.5 Healthcare Services in Norway
Norway Healthcare Services Market Forecast, 2022-2030 (in $Bn) xx
xx
xx
xx
xx
xx
xx
xx
xx
2022
2023F
2024F
2025F
2026F
2027F
2028F
2029F
2030F
▪
Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report
▪
In this section you will get an understanding of the overall Healthcare Services market in Norway, which includes the market size, current trends and other details related to the topic
▪
In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
▪
Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest
Illustrative
A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential 18
1.6 Healthcare Scenario in Norway
Cancer Drug Development Process: The process of developing a cancer drug is complex and involves many stages, from preclinical research to clinical trials to regulatory approval. Here is a simplified diagram of the cancer drug development process: o Preclinical Research: Researchers identify potential drug candidates and test them in the lab o Phase 1 Clinical Trials: Small studies are conducted to test the safety and dosage of the drug in humans o Phase 2 Clinical Trials: Larger studies are conducted to test the effectiveness of the drug in treating cancer o Phase 3 Clinical Trials: Even larger studies are conducted to compare the new drug to standard treatments and evaluate its safety and effectiveness
o Regulatory Approval: The drug is reviewed by regulatory agencies such as the FDA and approved for use in the US market FDA has developed several approaches to making drugs available as quickly as possible, while still ensuring their safety and effectiveness. Here are four of these approaches:
▪
Fast track is a process designed to facilitate the development, and expedite the review of drugs to treat Fast Track
serious conditions and fill an unmet medical need
Breakthrough
▪
A process designed to expedite the development and review of drugs which may demonstrate substantial Therapy
improvement over available therapy
Accelerated
▪
These regulations allowed drugs for serious conditions that filled an unmet medical need to be approved Approval
based on a surrogate endpoint
Priority Review
▪
A Priority Review designation means FDA’s goal is to take action on an application within 6 months Illustrative
A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential 19
1.6 Healthcare Scenario: Patient Journey
Presentation
Diagnosis
Treatment
Follow up
Confirmatory Diagnosis
Complete blood count
Prevention and management of
(evaluate number &
crisis:
quality of RBCs, Hb &
• For VOC and Splenic
• Long term follow-up is required for
WBCs)
patients with SCD
Initial Diagnosis
Sequestration: HU, Endari,
Adakveo, Oxbryta
• Annual assessment: CBC and
A suspected diagnosis is
Imaging (confirm bone
• For infections: Antibiotics,
reticulocyte count, iron status, liver
usually made, based on
related changes or
Vaccines
and renal function tests, urinalysis,
physical examination and
respiratory problems)
Prenatal screening/
LDH, vitamin D level and
detailed patient and family
Neonatal screening
Bacterial cultures of
neurocognitive assessment
history
blood, sputum, urine,
• ESOD (End Stage Organ Damage)
stool (detect any
Prevention and management of
evaluation starting from age 7
infection)
complications:
• Yearly Transcranial Doppler test to
determine risk of stroke
Genetic testing (detect
• Stroke: Chronic transfusions, HU
the type of SCD)
sr
PCP, pediatrician, neonatologist,
ed
endocrinologist, cardiologist,
l
PCP, paediatrician,
PCP, pediatrician, medical geneticist,
o
neonatologist,
PCP, pediatrician, medical geneticist,
hematologist, orthopedist, psychologist
cardiologist, hematologist,
haematologist and genetic
hematologist, gynecologist and pathologist
and psychiatrist
endocrinologist, psychologist and
counsellor
psychiatrist
Depending on the organ complications,
Stakeh
the treatment involves different
specialists at different times
Illustrative
A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential 20
1.7 Health Insurance Coverage: Norway
% of People by Type of Health Insurance Coverage
Number of People By Health Insurance Coverage
(2021)
Coverage Type
2020
2021
Change %
Uninsured
8.3
Total
327,521
328,074
With health insurance
91.7
Any health plan
299,230
300,887
0.4
Any private plan
217,896
216,366
–0.6
Any private plan
66.0
Employment-based
178,737
178,285
–0.2
Employment-based
54.3
Direct-purchase
10.2
Direct-purchase
33,869
33,555
–0.1
Marketplace
3.5
Marketplace coverage
10,924
11,389
0.1
TRICARE
2.5
TRICARE
9,165
8,299
–0.3
Any public plan
112,925
117,095
1.2
Any public plan
35.7
Medicare
58,541
60,226
0.5
Medicare
18.4
Medicaid
58,778
61,940
0.9
Medicaid
18.9
VA and CHAMPVA
2,967
3,151
0.1
VA and CHAMPVA
1.0
Uninsured
28,291
27,187
–0.4
▪
In 2021, most people (91.7%) had health insurance coverage at some point during 2021 and 8.3 % of people were uninsured for the entire calendar year
▪
More people had private health insurance (66%) than public coverage (35.7%)
▪
Employer-based insurance was the most common subtype of health insurance in the civilian, noninstitutionalized population (54.3%), followed by Medicaid (18.9%), Medicare (18.4%), direct-purchase insurance (10.2%), TRICARE (2.5%), and VA and CHAMPVA health care (1%)
Illustrative
A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential 21
1.8 Budget of Norway Government for Public Insurance
Proposed Budget By Category
Outlays
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2022-31
Medicare
$769
$709
$766
$841
$840
$947
$1,014
$1,085
$1,227
$1,178
$1,325
$1,412
$10,633
In Billions Of Dollars
Medicaid
$458
$521
$571
$582
$616
$645
$674
$698
$734
$768
$801
$837
$6,926
Medicare
3.7%
3.2%
3.3%
3.4%
3.3%
3.6%
3.7%
3.8%
4.1%
3.8%
4.1%
4.2%
3.7%
As % Of GDP
Medicaid
2.2%
2.4%
2.4%
2.4%
2.4%
2.4%
2.4%
2.4%
2.5%
2.5%
2.5%
2.5%
2.4%
▪
National Health Expenditures (NHE) grew 2.7% to $4.3 trillion in 2021, or $12,914 per person, and accounted for 18.3% of Gross Domestic Product (GDP)
▪
Medicare spending grew 8.4% to $900.8 billion in 2021, or 21% of total NHE
▪
Medicaid spending grew 9.2% to $734.0 billion in 2021, or 17% of total NHE
▪
Private health insurance spending grew 5.8% to $1,211.4 billion in 2021, or 28% of total NHE
▪
Out of pocket spending grew 10.4% to $433.2 billion in 2021, or 10% of total NHE
▪
Other Third Party Payers and Programs and Public Health Activity spending declined 20.7% in 2021 to $596.6 billion, or 14% of total NHE
▪
Hospital expenditures grew 4.4% to $1,323.9 billion in 2021, slower than the 6.2% growth in 2020
▪
Physician and clinical services expenditures grew 5.6% to $864.6 billion in 2021, slower growth than the 6.6% in 2020
▪
Prescription drug spending increased 7.8% to $378.0 billion in 2021, faster than the 3.7% growth in 2020
▪
Largest shares of total health spending were sponsored by the federal government (34%) and the households (27%). The private business share of health spending accounted for 17% of total health care spending, state and local governments accounted for 15%, and other private revenues accounted for 7%
Illustrative
A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential 22
1.9 Mergers and Acquisitions
RCM M&A Deal Value Trend ($Bn)
RCM M&A Deal Volume Trend
$16.7
112
107
107
110
89
$11.7
82
$10.5
$7.7
$6.8
$6.0
1H 2020
2H 2020
1H 2021
2H 2021
1H 2022
2H 2022
1H 2020
2H 2020
1H 2021
2H 2021
1H 2022
2H 2022
Buyer Composition: Strategic Vs Financial (2020)
Buyer Type by Deal Size
41%
41%
42%
39%
($Mn)
59%
59%
58%
61%
Strategic Buyers
Financial Buyers
$0- $25
$25-$50
$50-$100
$100+
57% of the total deal volume are done by strategic buyers and the rest 43% are done by financial buyers in 2020 Illustrative A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential 23
1.9 Mergers and Acquisitions (continued)
Latest Deals In Norway
Amount /
Company Name
Type
Year
Key Pointers
Duration
▪
Oracle’s acquisition of Cerner is big tech’s latest foray into the healthcare system, promising better outcomes
▪
Oracle acquire Cerner through an all-cash tender offer for $95.00
per share, or approximately $28.3 Bn in equity value
Acquisition
$28.3 Bn
June, 2022
▪
Cerner is a leading provider of digital information systems used within hospitals and health systems to enable medical
Oracle acquisition of
professionals to deliver better healthcare to individual patients Cerner
and communities
▪
GSK has acquire BELLUS for US$14.75 per share of common
stock in cash representing an approximate total equity value of US$2.0 billion
▪
BELLUS is a late-stage biopharmaceutical company working to Acquisition
$2 Bn
April 2023
better the lives of patients suffering from persistent cough
▪
Acquisition further strengthens specialty medicines and
respiratory pipeline with camlipixant, a highly selective P2X3
GSK acquisition of
antagonist and potential best-in-class treatment for refractory BELLUS Health
chronic cough
Illustrative
A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential 24
1.9 Mergers and Acquisitions (continued)
Latest Deals In Norway
Amount /
Company Name
Type
Year
Key Pointers
Duration
Merger
March 2023
Merger
Jan 2023
Illustrative
A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential 25
Norway Medical and Diagnostic Laboratory Service Market Analysis 2. Market Size and Forecasting
2.1 Market size and forecasts (Excel and Methodology)
Norway Medical and Diagnostic Laboratory Service Market Forecast, Click on the icon to know the
methodology and assumption
2022-2030 (in $Bn)
▪
Please be aware that this sample report
XX
is intended to provide you with a brief
XX
overview of the kind of information and
analysis that will be presented in the
final report
▪
In this section you will get an
understanding of the overall Healthcare
Insurance market in Norway, which
includes the market size, current trends
2022
2023F
2024F
2025F
2026F
2027F
2028F
2029F
2030F
and other details related to the topic
2023
2024
2025
2026
2027
2028
2029
2030
▪
In order to obtain access to all of the
Major Markets Patient
2.74
2.82
2.90
2.94
2.98
3.02
3.07
3.12
information that you are seeking, you
(Mn)
will need to purchase the final report
Norway Patient Size (Bn)
0.51
0.61
0.68
0.69
0.70
0.71
0.72
0.73
▪
Final report will be comprehensive and
detailed, and it will include data,
% of US Patients
18.75% 21.70% 23.56% 23.45% 23.42% 23.39% 23.34% 23.45%
analysis, trends, and other relevant
Global Market Size (Bn $)
3,620
3,780
3,950
4,128
4,314
4,508
4,711
4,937
information related to the topic or
subject matter of interest
Norway Market Size (Bn
61
74
84
87
91
95
99
106
$)
Illustrative
A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential 27
2.2 Snapshot of Norway Medical & Diagnostics Market Segmentation By Test
By Product
By End User
Lipid Panel
Instruments
Hospital Laboratories
Liver Panel
Reagents
Diagnostics Laboratory
Infectious Disease Testing
Other Products
Point of care Testing
Renal Panel
▪
In this section you will get an understanding of the segmentations which will cover the Norway Medical and Diagnostic Laboratory
Service Market Analysis
▪
In order to obtain access to all of the information that you are seeking, you will need to purchase the final report A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential 28
2.2.1 Market Segmentation: By Test
Norway Medical and Diagnostic Laboratory Service Market Share, By Test (2022)
▪
Lipid Panel in Norway is a significant
component of the overall cancer
treatment market
Renal Panel
▪
It has the maximum market share in
Norway market with approximately xx%
Lipid Panel
▪
Please be aware that this sample report
is intended to provide you with a brief
overview of the kind of information and
analysis that will be presented in the
final report
▪
In order to obtain access to all of the
information that you are seeking, you
will need to purchase the final report
Infectious
Disease Testing
▪
Final report will be comprehensive and
detailed, and it will include data,
Liver Panel
analysis, trends, and other relevant
information related to the topic or
subject matter of interest
Illustrative
A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential 29
2.2.2 Market Segmentation: By Product
Norway Medical and Diagnostic Laboratory Service Market Share, By Product (2022)
▪
Instrument in Norway is a significant
component of the overall cancer market
▪
It has the maximum market share in
Other Products
Norway market with approximately xx%
▪
Please be aware that this sample report
is intended to provide you with a brief
overview of the kind of information and
Intruments
analysis that will be presented in the
final report
▪
In order to obtain access to all of the
information that you are seeking, you
will need to purchase the final report
▪
Final report will be comprehensive and
detailed, and it will include data,
Reagents
analysis, trends, and other relevant
information related to the topic or
subject matter of interest
Illustrative
A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential 30
2.2.3 Market Segmentation: By End User
Norway Medical and Diagnostic Market Share, By End User (2022)
▪
Hospitals have the maximum market
share in Norway market with
approximately xx%
Point of Care
Testing
▪
Please be aware that this sample report
is intended to provide you with a brief
overview of the kind of information and
analysis that will be presented in the
final report
▪
In order to obtain access to all of the
information that you are seeking, you
Hospital
Laboratories
will need to purchase the final report
▪
Final report will be comprehensive and
detailed, and it will include data,
analysis, trends, and other relevant
Diagnostics
information related to the topic or
Laboratories
subject matter of interest
Illustrative
A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential 31
Norway Medical and Diagnostic Laboratory Service Market Analysis 3. Market Dynamics
3.1 Market growth drivers
3.1.1 Norway’s per capita health expenditure is also much higher than in most countries – over $5268.54 in 2021.
Public sources account for 85.5% of current health expenditure, which is the highest share in Europe.
▪
Norway has a robust healthcare system with a high level of public Incidence of Cancer in Norway
healthcare expenditure.
▪
The government's focus on healthcare infrastructure development, increasing healthcare budgets, and investment in advanced diagnostic technologies drive the growth of the medical and diagnostic laboratory services market.
▪
Technological advancements in diagnostic tools and techniques have revolutionized medical testing.
▪
Norway has been at the forefront of adopting innovative diagnostic technologies, such as molecular diagnostics, genetic testing, and advanced imaging techniques.
▪
The availability of state-of-the-art diagnostic equipment and techniques drives market growth.
2010
2022
2030
Illustrative
A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential 33
3.1 Market growth drivers (continued)
3.1.2 The mean age at birth increased between 2015 and 2023 in all of Norway, for both genders. The biggest gains were made in Oslo, where the life expectancy at birth rose from 71.9 years (71.4-57.2) in 2015 to 81.3 years (80.0-82.7) in 2023 for men and from 79.0 years (71.4-0) in 2015.
▪
Norway, like many developed countries, has an aging
population.
▪
The elderly population tends to require more medical testing and diagnostic services to manage age-related conditions
and chronic diseases.
▪
The aging demographic contributes to the growth of the
medical and diagnostic laboratory services market.
2010
2022
2030
Illustrative
A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential 34
3.1 Market growth drivers (continued)
3.1.3 Over the past 50 years, cardiovascular disease mortality in Norway has decreased dramatically, and the majority of deaths now occur in those over the age of 80. Every year, 32,000 new cases of cancer are discovered, and over 70,000 persons with cardiovascular disease are treated in hospitals and outpatient clinics.
Top countries that are leveraging technology
in their fight against cancer
Norway
Austria
Denmark
Norway is facing a rising burden of chronic diseases such as Belgium
cardiovascular diseases, diabetes, and cancer.
Spain
Italy
Netherlands
Sweden
The need for accurate and timely diagnosis, disease monitoring, and Singapore
Switzerland
treatment planning fuels the demand for medical and diagnostic laboratory Israel
services.
Australia
Canada
France
United Kingdom
China
South Korea
Germany
Japan
United States
Illustrative
A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential 35
3.2 Market restraints
3.2.2 Average cost of
3.2.3 In 2020, the average cost of
3.2.1 In 2022, the
developing a diagnostic
a laboratories services in Norway
average cost of a
technique that is ultimately
was over $785.68
diagnostic services in
approved by the regulatory
Norway was over
authority in Norway is over
$682.59
$1856.25
Regulatory processes and
The healthcare Laboratories market
Affordability can be a significant
compliance requirements can pose
in Norway is characterized by the
restraint for certain segments of the
challenges for companies operating
presence of multiple stakeholders,
population, particularly those with
in the healthcare diagnostics market.
including private laboratories,
lower income levels or inadequate
The approval and registration of
diagnostic centers, hospitals, and
health insurance coverage. The cost
diagnostic products, technologies,
government agencies. This
of healthcare diagnostics, including
and services by regulatory
fragmentation can lead to variations
laboratory tests, imaging
authorities can be time-consuming
in service quality, pricing, and
procedures, and specialized tests,
and costly. Compliance with quality
standards across different providers,
may pose financial constraints for
standards, data privacy regulations,
which may impact the overall market
individuals, impacting their ability to
and other regulatory aspects adds
consistency and create challenges in
access and undergo necessary
complexity to the market
standardization and coordination
diagnostic services
Our analysis will thoroughly investigate the key restraints that may significantly impact business
operations and growth.
Illustrative
A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential 36
Norway Medical and Diagnostic Laboratory Service Market Analysis 4. Competitive Landscape
4.1 Major Market Share
Revenue of Major players in Norway Medical and
▪
In order to obtain access to all of the
Diagnostic Laboratory Service Market ($ Mn)
information that you are seeking, you will
need to purchase the final report
Other
▪
Final report will be comprehensive and
detailed, and it will include data, analysis,
trends, and other relevant information
related to the topic or subject matter of
interest market
XX
Illustrative
A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential 38
4.2 Key Company Profile
Key Note:
1
Vestre Viken HF
▪
Here is the list of top 10 companies which
will cover in the final report
2
Fürst Medical Laboratory
▪
Each company will have slides for
o Overview
3
Sykehusapotekene
o Key details
4
Norgesplaster
o Offerings
o Name of products
5
Unilabs
o Recent activities/ Press Coverage
o Distribution and Vendor Partners
6
SYNLAB Norge
o Mergers, Acquisitions and
Collaboration
7
Aleris
o Financials
8
Quantum Diagnostics Sdn Bhd
▪
If there are specific companies that you
would like to be included in the report,
please let us know via email
9
Oslo University Hospital
▪
In order to obtain access to all of the
information that you are seeking, you will
Helse Bergen
10
need to purchase the final report
A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential 39
4.2.1 Vestre Viken HF
▪
Solutions offered by Adventa
One of Norway's biggest healthcare organisations is Vestre Viken Founded in: 30 March 2009
Berhad
HF. In the Vestre Viken region, which comprises the counties of Buskerud, Drammen, Kongsberg, Ringerike, and Hurum, it is a HQ: Drammen, Norway
➢ Diagnostics
health trust charged with delivering specialised healthcare services.
Type: Private
➢ Pharmaceuticals
▪ Several hospitals and healthcare institutions in the area are run
➢
Revenue: $ 1.489 Bn
Medical Services
by Vestre Viken HF. These facilities offer a broad range of healthcare services, such as emergency, surgical, and
➢ Clinical Trials
Website: https://vestreviken.no/
specialised care for patients with different medical specialties.
➢ Surgical Services
Recent Activity / Press Coverage
In 2023, Vestre Viken HF business model is to provide its Laboratories and Radiology services to public and Trust hospitals. Patients will be allowed to lease and take the machine home for a customised self-treatment programme at the cost of about $698.587 a month In February 2021, Vestre Viken HF announced plans to invest over $94.68 Mn in a new hospital in Drammen, Norway. The new hospital will be a state-of-the-art facility with 135,000 square meters of floor space and 350 patient rooms, and it is expected to be completed by 2029.
In 2021, Vestre Viken HF signed an agreement with GE Healthcare to implement a new digital pathology system across its hospitals. The system will allow for more accurate and efficient diagnoses, and it is expected to improve patient outcomes and reduce costs.
A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential 40
4.2.1 Vestre Viken HF (continued)
Partnerships Ecosystem
Major Distribution Partners
Major Vendor Partners
One of the largest pharmaceutical
Roche has been working with SAP, a
distributors in the United States, McKesson
leading software company, to develop digital
has been a long-standing distribution
solutions for its healthcare products
partner for Roche
Cardinal Health is a Fortune 500 healthcare
A leading Swiss biotechnology company,
services company that provides
Lonza provides Roche with contract
pharmaceutical distribution services to
manufacturing services for the production of
Roche
its biologics and pharmaceuticals
It is one of the largest drugstore chains in
Roche has a strategic partnership with
the United States and Europe, and its
Microsoft to leverage its cloud computing
extensive network of retail locations and
and AI technologies in the development of
distribution centers make it an important
new healthcare products
distribution partner for Roche
Thermo Fisher Scientific is a leading
A leading healthcare services provider in
provider of analytical instruments, reagents,
Asia, Zuellig Pharma is a distribution
and laboratory services
partner for Roche in several Asian countries
One of the largest pharmaceutical
GE Healthcare provides Roche with
wholesalers in Europe, PHOENIX Group
advanced medical imaging and diagnostics
distributes Roche's products in several
technologies, including CT scanners and
European countries
MRI machines
Illustrative
A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential 41
4.2.1 Vestre Viken HF (continued)
Latest Deals - Mergers and Acquisitions
Amount /
Company Name
Type
Year
Key Pointers
Duration
▪
Roche and Lilly will collaborate on the development of Roche Diagnostics’ Elecsys Amyloid Plasma Panel
▪
Elecsys Amyloid Plasma Panel has demonstrated clinical
Collaboration
-
March, 2023
performance and is currently undergoing additional investigation Lilly
to ensure clinical validation
▪
Once approved, could help healthcare professionals to streamline the journey to diagnosis for more patients
▪
Roche to acquire GenMark Diagnostics for US$ 24.05 per share with the expectation to close in the 2nd quarter of 2021
▪
GenMark provides molecular diagnostic tests that are designed to detect multiple pathogens from a single patient sample
Merger
$1.8 Bn
March 2021
GenMark Diagnostics
▪
GenMark’s ePlex platform delivers rapid and actionable results so clinicians can determine the cause of infection and the most effective treatment, potentially saving lives and alleviating the healthcare burden
Illustrative
A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential 42
4.2.1 Vestre Viken HF (continued)
Revenues ($Bn), 2020-2030
▪
According to Roche's 2020 financial report,
the company had sales of CHF 58.3 Bn
(Swiss Francs) in 2020
▪
This is equivalent to approximately $63.3
Bn USD, based on exchange rates at the
end of 2020
▪
Company's Pharmaceuticals Division
generated sales of CHF 49.9 Bn in 2020,
2020
2021
2022
2023F
2024F
2025F
2026F
2027F
2028F
2029F
2030F
while the Diagnostics Division generated
sales of CHF 8.4 Bn
Breakdown of Net Revenue by Segment, 2022
▪
Revenue generated by Roche in 2020
reflects the company's continued growth
and success in the healthcare industry
▪
In order to obtain access to all of the
information that you are seeking, you will
need to purchase the final report
1
2
3
4
Illustrative
A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential 43
4.2.2 Company 2
Solutions offered by Company
Founded in:
HQ:
Type:
Revenue:
Website:
Drugs for Cancer
Recent Activity / Press Coverage
Drugs
Indications
Illustrative
A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential 44
4.2.2 Company 2 (continued)
Partnerships Ecosystem
Major Distribution Partners
Major Vendor Partners
Illustrative
A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential 45
4.2.2 Company 2 (continued)
Latest Deals - Mergers and Acquisitions
Amount /
Company Name
Type
Year
Key Pointers
Duration
Illustrative
A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential 46
4.2.2 Company 2 (continued)
Revenues ($Bn), 2020-2030
▪
Please be aware that this sample report is
intended to provide you with a brief
overview of the kind of information and
analysis that will be presented in the final
xx
xx
xx
report
▪
In this section you will the understating of
financial overview of the company, which
includes revenue forecasting, segment
revenue and other key details as per
2020
2021
2022
2023F
2024F
2025F
2026F
2027F
2028F
2029F
2030F
availability
▪
In order to obtain access to all of the
Breakdown of Net Revenue by Segment, 2022
information that you are seeking, you will
need to purchase the final report
▪
Final report will be comprehensive and
detailed, and it will include data, analysis,
trends, and other relevant information
related to the topic or subject matter of
interest
1
2
3
4
Illustrative
A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential 47
Norway Medical and Diagnostic Laboratory Service Market Analysis 5. Reimbursement Scenario
5.1 Reimbursement Regulation
Medicare and Medicaid together provide
The reimbursement scenario in the US cancer market is complex and can vary health insurance coverage for more than
depending on the specific treatment, setting of care, and insurance coverage.
Here are some key points to consider:
4 in 10 Americans
▪
Medicare:
o Medicare is a federal health insurance program for people aged 65 and Other Public
older, as well as people with certain disabilities or health conditions 1%
o Medicare covers many cancer treatments, including chemotherapy, Other Private
radiation therapy, and some immunotherapies
3%
Uninsured
o
9%
However, coverage can be subject to strict guidelines and restrictions, Medicare
17%
such as the requirement for prior authorization
▪
Medicaid:
o Medicaid is a joint federal-state program that provides health insurance for people with low incomes
o Medicaid coverage for cancer treatments can vary by state, and may be Medicaid
and CHIP
subject to limits on the amount and type of treatment covered 21%
▪
Private Insurance:
o Private insurance coverage for cancer treatments can also vary widely depending on the insurer and the specific policy
Employer-Sponsored
49%
o Some policies may have high out-of-pocket costs, such as deductibles and co-pays, while others may have more comprehensive coverage Health Insurance Coverage, 2022
Illustrative
A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential 49
5.1 Reimbursement Regulation (continued)
▪
Affordable Care Act:
o Affordable Care Act (ACA) includes provisions to help improve access to cancer treatments by requiring insurers to cover certain preventive services, including cancer screenings, without co-pays or deductibles o It also includes protections for people with pre-existing conditions, such as cancer
▪
Reimbursement for New Treatments:
o Reimbursement for new cancer treatments can be a complex and lengthy process, as insurers and government programs often require evidence of safety and effectiveness before providing coverage o This can create challenges for companies developing and marketing new treatments
▪
Value-Based Care:
o There is a growing trend towards value-based care, which aims to improve outcomes and lower costs by focusing on the value of treatments rather than simply the volume of treatments o Value-based care models can include payment models that tie reimbursement to outcomes or performance metrics In order to obtain access to all of the information that you are seeking, you will need to purchase the final report Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest
Illustrative
A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential 50
5.1 Reimbursement Regulation (continued)
Coverage Penetration (% Total Population)
Source of Funding
Spend on Healthcare (%of Current Health Expenditure)
100%
100%
100%
100%
100%
0%
Government Expenditure
0%
xx
xx
xx
xx
xx
7%
%
Public Healthcare
44.
0
8%
46.
.
47.
15
51.
Private Health Insurance
Coverage
Out of Pocket
Private Coverage
9%
1%
6%
5%
5%
38.
37.
35.
32.
31.
Other
NA
NA
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
Public healthcare coverage is provided by the government and includes programs like Medicare and Medicaid
6.3%
4.08%
5.1%
3.8%
2.2%
2.4%
3.6%
GDP Growth (yoy)
Medicare is a federal program that provides healthcare coverage to individuals who are 65 years of age or older, as well as certain younger people with disabilities 14.7%
11.3%
15.5%
7.5%
4.2%
NA
NA
HC Spend Growth (yoy)
Medicaid is a joint federal-state program that provides healthcare coverage to individuals with low income and limited resources
Reimbursement Market Trends
▪ Shift towards value-based care has been a significant trend in the US healthcare system, with payers and providers increasingly focused on improving patient outcomes and reducing costs
▪ This has led to the development of alternative payment models such as accountable care organizations (ACOs) and bundled payment arrangements, which incentivize providers to deliver high-quality, cost-effective care Illustrative
A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential 51
5.2 Reimbursement Process for Diagnosis of Diseases
The reimbursement process in the US healthcare system can be complex and can vary depending on the type of healthcare service, the healthcare provider, and the insurance coverage. Here are the general steps involved in the reimbursement process:
▪
Service or Treatment Provided: The healthcare provider performs a service or treatment for the patient
▪
Billing: The healthcare provider submits a claim to the insurance company or other payer, requesting reimbursement for the service provided
▪
Adjudication: The insurance company or other payer reviews the claim to determine whether it meets the criteria for reimbursement. This can involve verifying the patient's eligibility, reviewing the treatment provided, and checking for any potential errors or fraud
▪
Payment: If the claim is approved, the insurance company or other payer reimburses the healthcare provider for the service provided, based on the negotiated payment rates or fee schedule
▪
Patient Responsibility: Depending on the patient's insurance coverage, they may be responsible for paying a portion of the cost of the service, such as deductibles, co-payments, or co-insurance In order to obtain access to all of the information that you are seeking, you will need to purchase the final report Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest
Illustrative
A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential 52
5.3 Reimbursement Process for Treatment of Diseases
The reimbursement process in the US healthcare system can be complex and can vary depending on the type of healthcare service, the healthcare FDA
provider, and the insurance coverage. Here are the general steps involved in the reimbursement process:
▪
Service or Treatment Provided: The healthcare provider performs a Market Authorization
service or treatment for the patient
▪
Billing: The healthcare provider submits a claim to the insurance company or other payer, requesting reimbursement for the service Private Payers
Public Payers
provided
▪
Adjudication: The insurance company or other payer reviews the claim to determine whether it meets the criteria for reimbursement. This can involve verifying the patient's eligibility, reviewing the treatment Health Technology Assessment
provided, and checking for any potential errors or fraud
▪
Payment: If the claim is approved, the insurance company or other 1
2
3
payer reimburses the healthcare provider for the service provided, Coding
Coverage
Payment
based on the negotiated payment rates or fee schedule
Coding depends on availability code while coverage and
payment process decisions are made through an HTA.
Illustrative
A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential 53
5.4 Reimbursement Process - Medicare
Medicare
▪ 100% population is covered under this scheme
Population Covered
▪ Citizen’s contribute to this scheme which then earns an interest. There is Basic Healthcare Sum (BHS) cap which limits the maximum contribution to an individuals Medicare account
Provider Restrictions/
Services can be claimed from Medicare-approved institutions only (14 public hospitals, 10 private hospitals, 7 public community centers, 1 private community Selection
center and over 100 surgery centers, dialysis centers, colonoscopy centers and screening centers)
▪ Medicines under SDL and MAF Plus can be bought from the money saved in this account
▪ Money can be also be claimed for antiretroviral drugs for HIV, Desferrioxamine drug for treatment of thalassemia and immuno-suppressant drugs for organ transplant
▪ Money from this account can be used to pay Medishield premiums and Integrated Shield Plan premiums, subject to withdrawal limits Services Covered
▪ Patients above 65 years of age can claim under Flexi-Medicare and further reduce their out-of-pocket expenses by using up to $200 per patient per year from their Medicare account
▪ Excluded: Traditional drugs such as Herbal and Ayurveda cannot be claimed from Medicare account; Drugs used for cosmetic purposes such as slimming pills and hair loss pills cannot be claimed from this account
▪ Approved chronic conditions and vaccinations, health screenings as outpatient treatments can be paid with Medicare up to $500 per account per year, however a cash copayment of 15% is applicable
▪ Inpatient hospitalization, up to $450 per day + surgical limits according to Table of Surgical Procedures
▪ Approved day surgeries up to $300 per day + surgical limits according to Table of Surgical Procedures Level of Coverage/ Assurance
▪ Outpatient scans/ diagnostics for cancer up to $600 per year per patient, and up to $300 for other medical conditions
▪ Chemotherapy (includes analgesic medication and suppressive treatments such as neuroendocrine and nuclear medicine treatments) up to $1,200 per month per patient
▪ Renal dialysis up to $450 per patient per month
▪ Other treatments are also approved with various sub-limits for withdrawal
▪ DRG with Activity Based Funding for public providers
Mechanism of Coverage
▪ Block funding with DRG for providers not covered under ABF
Financial Feasibility
▪ The Basic Healthcare sum has been increased by more than 4.4% in 2017 on account of increasing costs of healthcare. This is an individual account Illustrative
A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential 54
5.5 Reimbursement Process - Medicaid
Medicaid
▪ 38% population is covered under this scheme
Population Covered
▪ Medicare covers individuals who are aged 65 and older, as well as those with certain disabilities or end-stage renal disease Provider Restrictions/
Services can be claimed from Medicaid-approved institutions only (14 public hospitals, 10 private hospitals, 7 public community centers, 1 private community Selection
center and over 100 surgery centers, dialysis centers, colonoscopy centers and screening centers)
▪ Medicines under SDL and MAF Plus can be bought from the money saved in this account
▪ Money can be also be claimed for antiretroviral drugs for HIV, Desferrioxamine drug for treatment of thalassemia and immuno-suppressant drugs for organ transplant
▪ Money from this account can be used to pay Medishield premiums and Integrated Shield Plan premiums, subject to withdrawal limits Services Covered
▪ Patients above 65 years of age can claim under Flexi-Medicaid and further reduce their out-of-pocket expenses by using up to $200 per patient per year from their Medicaid account
▪ Excluded: Traditional drugs such as Herbal and Ayurveda cannot be claimed from Medicaid account; Drugs used for cosmetic purposes such as slimming pills and hair loss pills cannot be claimed from this account
▪ Approved chronic conditions and vaccinations, health screenings as outpatient treatments can be paid with Medicaid up to $500 per account per year, however a cash copayment of 15% is applicable
▪ Inpatient hospitalization, up to $450 per day + surgical limits according to Table of Surgical Procedures
▪ Approved day surgeries up to $300 per day + surgical limits according to Table of Surgical Procedures Level of Coverage/ Assurance
▪ Outpatient scans/ diagnostics for cancer up to $600 per year per patient, and up to $300 for other medical conditions
▪ Chemotherapy (includes analgesic medication and suppressive treatments such as neuroendocrine and nuclear medicine treatments) up to $1,200 per month per patient
▪ Renal dialysis up to $450 per patient per month
▪ Other treatments are also approved with various sub-limits for withdrawal
▪ DRG with Activity Based Funding for public providers
Mechanism of Coverage
▪ Block funding with DRG for providers not covered under ABF
Financial Feasibility
▪ The Basic Healthcare sum has been increased by more than 4.4% in 2017 on account of increasing costs of healthcare. This is an individual account Illustrative
A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential 55
Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis 6. Methodology & Scope
▪
Insights 10’s research methodology delves deeper into the market, covering the macro and micro aspects of the industry. We identify the key growth drivers, opportunities, and restraints that might promote or hinder the future industry growth along with an expansive overview of the competitive landscape to help our clients make informed strategic decisions
▪
We implement a mix of primary and secondary research for our market estimate and forecast. The secondary research forms the initial phase of our study where we conduct extensive data mining, referring to verified data sources such as independent studies, government and regulatory published material, technical journals, trade magazines, and paid data sources
▪
For forecasting, the following parameters are considered:
❑
Market drivers and restraints along with their current and expected impacts
❑
Technological scenario and expected developments
❑
End use industry trends and dynamics
❑
Trends in the consumer behavior
❑
Regulatory scenario and expected developments
❑
Current capacity and expected capacity additions up to 2030
▪
We assign weights to these parameters and quantify their market impacts using the weighted average analysis to derive the expected market growth rate
▪
We appoint data triangulation strategies to explore different areas of the market. Our qualitative and quantitative assessments are time-sensitive, reflecting the most recent value and volume of the market across regions
▪
All our estimates and forecasts are verified through exhaustive primary research with the Key Industry Participants (KIPs)
▪
Currency used in the report is the US dollar (USD), with the market size indicated in USD million/billion (Mn/Bn)
Analysis Methodology
Our Analysis Methodology involves three critical stages:
Data
Market Data Analysis
Interpretation &
Collection
& Statistical Model
Presentation
Secondary
Analysis &
Market Trends
Research
Interpretation
Primary
Market Sizing &
Insights
Research
Analysis
Proprietary
Data Triangulation &
Presentation &
Database
Validation
Reporting
Data Triangulation & Data Validation
Top Down Approach
Final
Final Market size break up to
Market
rest of segmentation
Size
Validation from
Arriving at market size
Primary Interview
of each segment
Summarization of revenue
generated from companies
Validation from
to arrive at total market size
Primary Interview
Revenue generated by products &
Final
services offered by companies
Summary
Bottom Up Approach
Key Benefits for Stakeholders from this Report Study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent investment pockets
Our tools provides stakeholders with a cohesive understanding of the industry outlook, considering the qualitative and quantitative industry variables
Comprehensive analysis of factors that drive and restrict the market growth is provided Comprehensive quantitative analysis of the industry from 2022 to 2030F is provided to enable the stakeholders to capitalize on the prevailing market opportunities
Extensive analysis of the key segments of the industry helps understand the applications and technologies used globally Our rigorous data collection, thorough statistical analysis and specialist assessments ensure that our clientele has a greater understanding of the industry space, supply chain, price fluctuations, competitive landscape, and other vital factors
Time Frame
Report Attribute
Details
Quantitative Units
Revenue in USD Million/Billion (Mn/Bn)
Base Year for
2022
Estimation
Market Overview, Revenue Forecast, Market
Segmentation, Growth Factors and Trends,
Report Coverage
Company Profiles, Competitive Landscape,
Regulatory Landscape, Future Opportunities
Report Customization (3 to 5 working days)
with purchase. We will provide you with data
Customized Report
that is currently not a part of our scope as a
2023-
Forecast
part of customization
2030
Period
Pricing and purchase
Avail customized purchase options to meet
options
your exact research needs
A division of
Lifesciences Market
Research Reports you
can trust
Insights10 is a healthcare focused market
research firm founded with an aim of being an
insights driven company in the data driven world
and delivering actionable insights that can drive
decision and strategy making process for
businesses
Get actionable insights to
take informed business
decisions
A large database of over 30,000 syndicated
market research reports in Healthcare Services
and healthcare sector at global, regional as well as
country level. We also provide customized
research reports tailor made to suit your needs
Elevate your business plans
with in-depth market analysis
and industry intelligence
Our qualitative, acute, and result-oriented market
research reports provide a comprehensive
understanding of the business scenario and the
latest trends related to the life sciences market
Gain a competitive edge with
Insights10's customized
healthcare research solutions
Whether you are looking to expand into new
areas, develop new products, or take advantage
of new opportunities we have reports to help you
accelerate and improve your plans by identifying
unique growth prospects.
Market Research Reports
across various categories
Healthcare Services
Digital
Medical
Healthcare
OTC &
Clinical
(Diseases & Drugs)
Health
Devices
Services
Nutraceuticals
Trials
FEATURED REPORTS
FREE SAMPLE REPORTS
TRENDING TOPICS
What makes us different?
30000+
22000+
2000+
1200+
Life science
Country
Rare & orphan
Reports
Market Research
Specific
Disease
Published
Reports
Reports
Reports
Annually
Table of Contents
Market Overview
Competitive Landscape
1
6
Growth Drivers &
Key Company Profiles
2
7
Growth Restraints
Epidemiology &
Policy & Regulatory
3
8
Disease type
Landscape
insights on
which our
reports are
Market Segmentation
based
4
9
Reimbursement Scenario
Market Share
5
10
Factors Driving Future Growth
Our Services
Market Research
Customized
Primary
Reports
Reports
Research
Database
Full-Time
Conference
Service
Engagement
Coverage
Competitive
Regulatory
Subscription
Intelligence
Compliance
Over the years, we have developed an in-depth experience of executing market analysis at global, regional & country specific level in life sciences.
Our team has
conducted market
research across 62+
global markets in
America, Europe,
Middle East, Africa and
Asia Pacific regions
Research Projects Done
Our Research Process
01
02
03
04
05
Identification of
Market
Collection of
Collaboration
Verification &
Data
Dynamics
Data
of Data
Analysis
Statistical Databases
Company Websites/Annual Reports
Data
Sources
Trade Publications
We have access to multiple highly
Online Databases
reliable free and subscription data
sources. We have many years of
experience to understand which
Published Research Reports
sources are more dependable for what
and which to prefer for the reliable and
Whitepapers
latest information.
Press Releases of Key Market Players
What kind of data is presented
in our reports?
Our reports present data, which is:
Reliable
Expert-verified
Real
Comprehensive
Easy to read
The report is
The data is prepared
Allowing you to
Covers everything
You do not have to
prepared using a
by a team of highly
confidently make
you would need to
be a market expert
proven methodology
qualified &
smarter business
know about the
to understand what
and insightful
experienced research
and strategic
market including
really is happening
research
analysts & vetted by
decisions
market size,
on the market and
our local associates
competitive analysis
how it works
& much more
The team
“The business decision-making process is no longer as straightforward as it used to be. It requires insights generated at the right time, based on reliable data
interpreted in a nuanced manner for each market.
We at Insights10 are building the future of market
research and are committed to providing our clients with the right intelligence and insights to make business
decisions quickly and efficiently.
Insighs10 is a unique platform that combines deep
domain expertise, nuanced data at a country and
functional area level, and years of experience working with some of the best organizations in the world,
generating insights that provides substantial competitive advantage.”
Dr. Purav Gandhi
Founder & CEO
Leadership Team
Dr. Purav Gandhi
Anish Swaminathan
Mukesh Nayak
Ritu Baliya
Founder & CEO
Director
Head – Marketing & Research
Engagement Manager
Purav is a physician and an entrepreneur
Anish has 15+ years of experience
Mukesh is an engineering graduate with
Ritu has over 6 years of experience in
with 12+ years of experience in Healthcare
in management consulting in the
an MBA in Marketing. He is a seasoned
strategy building, market assessments,
& Life Sciences industry spanning across
Life Sciences sector, and has
healthcare market research & marketing
market sizing, and RWE for global MNC
strategy, market access, health informatics
worked with diverse multinational
professional with a progressive
healthcare & biopharma clients across diff.
and RWE, digital health, analytics and data
firms in the US, India, Middle East
experience of over 20 years in Life
markets (America, Europe, Africa, APAC
science. Purav studied medicine from
and APAC regions. His primary
Sciences, Pharma and Medical Device
and Middle East). Her areas of expertise
Gujarat University and also completed his
area of interest is Customer and
sectors. With an in-depth understanding
include: Indentifying emerging trends in life
MBA from IIM-Kozhikode. Purav started
Market Strategy, Market Access,
of primary research, he has conducted
sciences industry, Competitor landscape
his career with Deloitte working on strategy
and Digital Health with special
hundreds of interviews of various
assessment, Disease opportunity
consulting engagements and also co-
focus on emerging markets like
stakeholders in pharma & healthcare &
assessments etc. She is a pro in secondary
founded ConvergeHealth by Deloitte.
Africa, Middle East and APAC.
completed several research projects
and primary research with a deep domain
across life sciences industry.
expertise in healthcare sector.
Our Team
Our Clients
Our Clients
… and many more
Do you have
any questions?
We would be happy to help.
Web: www.insights10.com
Email: insights@insights10.com
Call: (+91) 931 639 7935
WhatsApp: (+91) 931 639 7935
Thank you
We truly appreciate your business and
look forward to serving you.
www.insights10.com
